Amnol Chimica Biologica S.r.l.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Amnol Chimica Biologica S.r.l. - overview

Established

1978

Location

Novara, -, Italy

Primary Industry

Pharmaceuticals

About

Based in Novara, Italy, and founded in 1978, AMNOL Biological Chemistry Srl operates as a provider and manufacturer of pharmaceuticals, such as health products for phlebology and lymphology. As of 2023, the company is led by its CEO, Giorgio Stefanelli. In May 2023, Ceres Pharma NV, a portfolio company of Naxicap Partners, acquired Amnol Chimica Biologica S. r.


l.   The company is actively involved in conducting research and innovation in the field of biotechnology, resulting in the development of multiple patents in collaboration with renowned European pharmaceutical companies. Their product range encompasses health supplements, medical devices, and specialized equipment for phlebology, lymphology, and skin wellness. Additionally, the company offers health pills such as Lymphoguard, Lipolipase, Venovigor, and Wasotonal, which further contribute to their client's well-being.


Current Investors

Ceres Pharma NV

Primary Industry

Pharmaceuticals

Sub Industries

Pharmaceutical Research & Development

Website

www.amnol.net

Verticals

Manufacturing

Company Stage

Add-on

Total Amount Raised

Subscriber access only

Amnol Chimica Biologica S.r.l. - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
Add-onCompletedAmnol Chimica Biologica S.r.l.-

Displaying 1 - 1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.